Biomedical subjects

Fulian Hu

Publications and source records attributed to Fulian Hu.

3 recordsLinked to original sources

PubMed2004

Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia.

Many studies have investigated the expression of c-met and c-erbB2 protein in human gastric adenocarcinomas, but the expression of gastrin protein in human gastric cancer and the relationship between gastrin and c-met are unknown. We have constructed a tissue microarray containing 408 formalin-fixed and paraffin-embedded human tissue blocks, including tissues containing intestinal metaplasia (IM, n=72) and primary tumors (n=232), as well as normal gastric mucosa (n=104) from patients with gastric cancer. Immunohistochemistry (IHC) was used for detecting gastrin, c-met and c-erbB2 proteins. Gastrin was detected in 13.5% (7/52) and c-met in 15.3% (11/72) of IM cases. In gastric carcinomas, 48.4% (103/213) of cases expressed gastrin, 68.8% (148/215) expressed c-met, and 5.5% (11/200) expressed c-erbB2. Gastrin and c-met protein expression were significantly higher in gastric tumor tissue than in IM (P<0.0001). Overexpression of c-erbB2 protein was detected in gastric carcinomas but not in normal gastric mucosa (P<0.05). Expression of gastrin and c-met protein was associated (P<0.01), but no significant difference was found on the changes of gastrin, c-met and c-erbB2 expression in gastric cancer with tumor stage, grade of differentiation or tumor type. These results indicate that gastrin and c-met play a role in the early process during malignant transformation of the gastric mucosa.

Adenocarcinoma↗

PubMed2002

[Gastroenterology].

Explore the source record for details and available documents.

Biomedical Research↗

PubMed2002

[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].

OBJECTIVE: To compare the efficacies of pantoprazole and omeprazole-based triple regimens in the treatment of H. pylori infection for 1-week or 2-week. METHODS: 147 patients with H. pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks). The eradication was determined by (13)C-UBT at least 4 weeks after antibiotic therapy. RESULTS: The eradication rate of H. pylori for 1-week pantoprazole triple regimen and omeprazole triple regimen were 85.7% (42/49) and 76.9% (20/26) respectively (P > 0.05). The eradication rates of H. pylori for 2-weeks and pantoprazole triple regimen and omeprazole triple regimen were 93.9% (31/33) and 82.1% (32/39) for 2-week respectively (P > 0.05). CONCLUSION: The eradication rate of H. pylori in pantoprazole (or omerazole) triple therapy regimen for 2-weeks was higher than 1-week. However there were no significant difference between in these two groups (P > 0.05). There were no significant difference between pantoprazole and omeprazole triple therapy regimen in eradication rate of H. pylori for 1-week or 2-weeks (P > 0.05).

2-Pyridinylmethylsulfinylbenzimidazoles↗